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Residual viral replication persists in a significant proportion of human immunodeficiency
virus (HIV)–infected patients receiving potent antiretroviral therapy. To determine the source
of this virus, levels of HIV RNA and DNA from lymphoid tissues and levels of viral RNA
in serum, cerebrospinal fluid (CSF), and genital secretions in 28 patients treated for 2.5
years with indinavir, zidovudine, and lamivudine were examined. Both HIV RNA and DNA
remained detectable in all lymph nodes. In contrast, HIV RNA was not detected in 20 of 23
genital secretions or in any of 13 CSF samples after 2 years of treatment. HIV envelope
sequence data from plasma and lymph nodes from 4 patients demonstrated sequence diver-
gence, which suggests varying degrees of residual viral replication in 3 and absence in 1 patient.
In patients receiving potent antiretroviral therapy, the greatest virus burden may continue to
be in lymphoid tissues rather than in central nervous system or genitourinary compartments.
The seeding of lymphoid tissues and the propagation of virus
by CD4 cells (principally T lymphocytes) is established early
in the course of infection for both human immunodeficiency
virus (HIV) and experimental models of simian immunodefi-
ciency virus infection [1–4]. Throughout subsequent years of
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infection, the lymphoid tissues support most HIV replication,
and trapping of virus within the follicular dendritic cell (FDC)
network represents the bulk of the virus burden in the bodies
of untreated patients [5, 6]. The response to antiviral therapy
of virus and provirus present in this critical tissue compartment
is of paramount importance to the long-term success of any
treatment strategy. Thus, previous demonstrations of the rapid
initial reduction of lymphoid tissue virus load in response to
highly active antiretroviral therapy (HAART) over periods of
6 months to 1 year were encouraging [7–10].
However, several studies now suggest that incomplete sup-
pression of replication occurs in 50% of patients who achieve
targeted reductions of plasma virus load to !50 HIV RNA
copies/mL, as ascertained by evidence of sequence evolution
[11, 12], detection of spliced mRNA [13], or unintegrated viral
DNA [14, 15]. In 2 studies, evidence for incomplete suppression,
based on sequence evolution or failure of reduction in the fre-
quency of latently infected cells, seemed to correlate with the
sporadic reappearance of very low levels of detectable viremia
while receiving therapy or with a less rapid decay of plasma
viremia during initiation of therapy [11, 16]. Of importance,
with the exception of one study that examined lymph node
(LN) samples from 2 patients [12], the studies that suggested
incomplete viral suppression on HAART were based primarily
on studies of peripheral blood and did not directly examine the
possibility that replication occurs in anatomically isolated sites,
although such a scenario has been suggested [17]. Two candi-
JID 2001;183 (1 May) Residual HIV after Viremia Suppression 1319
date sites are the central nervous system (CNS) and genito-
urinary (GU) tract, which may harbor genetically discrete virus
variants with the added complexity of variable access for anti-
viral compounds [18–21]. In the formulation of more effective
treatment strategies, it will be necessary to determine whether
complete suppression of viral replication will depend on treat-
ments with greater activity in the blood and lymphoid com-
partments or on the introduction of new drugs with better CNS
or GU tract penetration or both.
The present study was undertaken to ascertain whether the
early phase clearance of virus from lymphoid tissues, cerebro-
spinal fluid (CSF), and genital secretions are sustained during
long-term therapy and to determine which, if any, of these tissue
reservoirs contribute to residual viral replication. Viral RNA
and DNA levels from LN biopsy specimens and viral RNA
from genital secretions and CSF were evaluated in patients who
had achieved reductions of virus load to !50 copies/mL for
2.5 years while receiving potent antiretroviral therapy (np
). An additional 3 patients had sustained virus loads 150025
copies/mL at the time of study during treatment with indinavir
(Idv), zidovudine (Zdv), and lamivudine (3TC). In a subset of
the LN biopsy specimens, we used in situ hybridization (ISH)
with quantitative image analysis (QIA), to identify residual viral
RNA in individual cells or the FDC network. For 4 patients,
partial HIV-1 env sequences from baseline plasma and year 1
or year 2 LN biopsy specimens or both could be evaluated for
evidence of sequence evolution as an indicator of ongoing viral
replication. We believe that the present work represents the first
comprehensive study that attempts to simultaneously investi-
gate virus load in 4 different compartments in a well-charac-
terized study population receiving successful long-term anti-
retroviral therapy [22] with validated assays [23].
Methods
Patients. This study cohort comprised 28 participants from
the Merck 035 study [22, 24, 25]. Patients were randomized initially
to either Idv ( ), Zdv plus 3TC ( ), or Idv, Zdv, plus 3TCnp 7 np 3
( ). After 6–12 months, patients were switched to open-labelnp 18
Idv, Zdv, plus 3TC. Patients were asked to volunteer for the present
study when serum HIV RNA levels were !500 copies/mL for 72
weeks. Patients had study visits at least every 4 weeks through
week 52 and every 8 weeks thereafter. At the time of lumbar punc-
ture, LN biopsy specimens or genital secretions were obtained, and
3 patients showed therapeutic failure with high serum RNA levels
(group 3; table 1). LN biopsy specimens were obtained from 20
patients, according to published procedures [8]. A subset of these
patients ( ) and an additional 3 patients had CSF evaluationsnp 10
( ). For 16 patients with LN biopsy specimens and for annp 13
additional 7 without LN biopsy specimens, we evaluated virus
loads in genital secretions ( ). Ten patients participated in allnp 23
3 substudies (LN, CSF, and GU).
Quantitation of HIV RNA and DNA. Serum HIV RNA levels
were measured by the Amplicor HIV Monitor test (Roche Diag-
nostic Systems), as described elsewhere [22]. If the result from this
assay was !500 copies/mL, we did the Roche ultrasensitive assay,
with a detection limit of 50 HIV RNA copies/mL [25]. Tissue RNA
and DNA quantitation and extraction methods have been de-
scribed in detail elsewhere [8]. The Roche ultrasensitive assay was
adapted to RNA extracted from LN tissues. RNA extracts were
treated with DNase and RNA was re-extracted. HIV RNA was
normalized to T cell receptor (TCR) Ca mRNA. LN HIV proviral
DNA was quantitated by a semiquantitative polymerase chain re-
action (PCR) assay for HIV-1 gag after RNase treatment and was
controlled by using PCR assay for b-actin. LN samples were
deemed to be inadequate for RNA quantitation when TCR Ca
RNA was !12,500 RNA copies, which is the equivalent of 500 T
cells. CSF RNA was measured by applying the ultrasensitive ver-
sion of the Amplicor assay to 500 mL of CSF, according to the
manufacturer’s protocols for serum [23, 28]. Genital secretions were
processed, as described in published protocols [29–31], and HIV-1
RNA was quantitated on cell-free fractions by the NucliSens assay
(Organon Teknika). We assayed seminal fluid from male patients
and vaginal swab, vaginal lavage washings, and cervical swab speci-
mens from female patients. Among the 3 patients with detectable
virus load in GU secretions, 1 was from seminal plasma, 1 was
from vaginal lavage, and 1 was from a cervical swab. Parafor-
maldehyde-fixed LN samples were analyzed by ISH with QIA [9].
Clonal sequencing. Amplification of env sequences was at-
tempted from LN specimens of 8 patients. PCR amplification was
positive in 6 of the 8; however, we excluded 2 of these 6 patients
from further evaluation because baseline sequences were contami-
nated with pNL4-3 sequences in 1 and because a rebound of serum
HIV RNA occurred just before the LN biopsy in the other. Four
patients were included for final analysis (3 LN biopsies at years 1
and 2 and 1 LN biopsy at year 1). After reverse transcription, a 350-
bp fragment that included the C2 and V3 region of HIV-1 env was
PCR amplified in quadruplicate from baseline serum and RNA ex-
tracts from LN biopsy specimens [11]. PCR amplifications on serum
and LN extracts were done in separate experiments, to minimize
intrapatient contamination, which would be difficult to exclude by
phylogenetic analysis. Quadruplicate nested PCR products were
pooled and cloned into the TOPO TA cloning system (Invitrogen),
and 10–18 clones per pooled PCR sample were selected and amplified
in culture. Plasmid DNA was extracted and was bidirectionally se-
quenced by use of Big Dye dideoxy terminator cycle sequencing [11].
Sequence analysis. For each patient, the total diversity within
each population and the total and net divergence (total divergence
minus the average within-population diversity) between each sampled
population was calculated by assuming a Tamura and Nei [32] model
of substitution, with SEs calculated from 1000 bootstrap replicates
with the SENDBS computer program [33]. Maximum likelihood
trees under a Tamura-Nei model were obtained by using a heuristic
search implemented in PAUP 4.0 [34] and other methods.
Estimation of residual viral replication. Residual viral repli-
cation was expressed as the net area under the curve (AUC) of
serum HIV RNA over time for patients 2, 3, 19, and 27. AUC net
was calculated by subtracting a predicted AUC, according to the
long-lived infected cell model of Perelson et al. [35], from the AUC
observed, as calculated by summation of trapezoids implemented
in the program PRISM 2.0. (Graphpad), as described elsewhere in
detail [11].
Nucleotide sequence accession numbers. All sequences reported
Table 1. Patient characteristics and results of bulk human immunodeficiency virus (HIV) RNA and DNA measurements in lymph nodes (LNs), cerebrospinal fluid (CSF), and
genitourinary (GU) secretions.
Group, patienta Therapyb
Log10 HIV RNA
copies/mL of serum
at baseline
Log10 HIV RNA
copies/mL of
serum at year 2
Time
suppressed
at year 2
Log10 HIV RNA copies/
4  106 LN/TCR
Ca mRNA at year 2
HIV DNA
copies/100 ng
in LN at year 1c
HIV DNA
copies/100 ng
in LN at year 2
HIV RNA
copies/mL of
CSF at year 2
HIV RNA
copies/mL of
GU secretions
at year 2
Group 1
1 (A) Zdv/3TC/Idv 5.15 !1.69 2 2.20   NA !400
2 (C) Zdv/3TC/Idv 5.23 !1.69 2 3.10   NA !400
3 (B) Zdv/3TC/Idv 4.74 !1.69 2 2.40   NA 470
4 (N)d Zdv/3TC/Idv 4.43 1.88 2 2.11 NA  NA NA
5 Zdv/3TC/Idv 4.38 !1.69 2 2.50 NA  !50 !400
6 Zdv/3TC/Idv 5.09 !1.69 2 0e NA f !50 !400
7 Zdv/3TC/Idv 4.73 1.77 2 2.74 NA  !50 !400
8 Zdv/3TC/Idv 4.17 !1.69 2 2.87 NA  !50 !400
9 (L) Idv 4.14 !1.69 2 2.43 NA  NA NA
10 Zdv/3TC/Idv 4.52 !1.69 2 2.87 NA NAg !50 !400
11 Zdv/3TC/Idv 4.95 1.92 2 4.73 NA NAg !50 !400
12 Zdv/3TC/Idv 4.79 !1.69 2 4.19 NA NAg !50 !400
13 Zdv/3TC/Idv 4.41 !1.69 2 0e NA NAg !50 !400
14 Idv 3.84 !1.69 2 NA NA NA !50 NA
15 Zdv/3TC/Idv 5.34 2.93 2 NA NA NA !50 1600
16 Idv 4.21 !1.69 2 NA NA NA !50 !400
17 Zdv/3TC/Idv 4.44h !1.69 2 NA NA NA NA !400
18d Zdv/3TC/Idv 4.98 !1.69 2 NA NA NA NA !400
Group 2
19 (I) Zdv/3TC 5.12 !1.69 1 3.18   NA 450
20 (O) Zdv/3TC 4.35 !1.69 1 3.40 NA  NA !400
21 Idv 5.00 !1.69 1 0e NA NAg NA !400
22 Idv 4.36 !1.69 1 0e NA NAg !50 !400
23 Zdv/3TC/Idv 3.88 !1.69 1 NA NA NA NA !400
24 Idv 5.00 !1.69 1 NA NA NA NA !400
25i Zdv/3TC/Idv 4.01 !1.69 2 NA NA NA NA !400
Group 3
26 Idv 4.15 3.38 0 5.77 NA  !50 !400
27 (G) Zdv/3TC 4.95 3.25 0 6.38   NA NA
28 Zdv/3TC/Idv 4.65 3.31 0 6.76 NA NA NA NA
NOTE. Results of LN DNA quantitation are expressed as follows: , !1 HIV DNA copy/100 ng of genomic DNA (but detectable on analysis of 400 ng of genomic DNA); , 1–10 copies; ,
10–50 copies; , 150 copies. 3TC, lamivudine; Idv, indinavir; NA, not available; TCR, T cell receptor; Zdv, zidovudine.
a Capital letters indicate patient designations used elsewhere [8, 11, 26, 27].
b Therapy during initial 6–12 months of study. After 6–12 months of study, treatment was changed to Zdv/3TC/Idv for all patients.
c HIV DNA from year 1 from patients 1, 2, 3, 19, and 27 were reported elsewhere, corresponding to designations A, B, C, G, and I [8].
d At week 28, patient 4 showed a transient serum HIV RNA level of 35,140 copies/mL, but serum RNA was not detectable 5 days later. Patient 18 had a transient RNA level of 7850 copies/mL. Both
transient RNA levels probably were erroneous.
e LN samples from these patients had no measurable TCR Ca message (!500 T cell equivalents), rendering HIV quantitation invalid.
f Despite insufficient cellularity of HIV RNA, HIV DNA was detected from different tissue section of same LN.
g HIV DNA was not assessed because of insufficient tissue for DNA extraction.
h At baseline, no serum RNA level was available; value was obtained at week 2 after initiation of therapy.
i In patient 25, HIV RNA values at weeks 28, 32, 36, 40 were 53,840, 1480, 600, and 128 copies/mL, respectively. Viral rebound was due to therapy interruption. Subsequent RNA levels up to week 124
were undetectable, apart from 149 copies/mL at week 68.
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Table 2. Comparison of year 1 and year 2 human immunodeficiency virus type 1 (HIV-1) RNA concentrations
between bulk reverse transcription–polymerase chain reaction and in situ hybridization with quantitative image
analysis.
Patienta
Approximate
years of
negative
viremia
Bulk quantitation,
log HIV-1 RNA
copies/g of
lymphoid tissue
In situ hybridization
Log HIV-1 RNA
copies/g of
lymphoid tissue
Log frequency of mononuclear
cells/g of lymphoid tissue
LN FDC LN MNC With 120 RNA With few RNA
1 (A) 2 3.50 !4 — 4.4
3 (B) 2 4.20 !4 — 3.7
2 (C) 2 4.80 !4 — !3
9 (L) 2 3.69 !4 — !3
4 (N) 2 3.19 !4 — !3
Mean 2 year 3.88
1 (A)b 1 4.85 !4 — 3.1
3 (B)b 1 4.85 !4 — !3
2 (C)b 1 5.19 !4 — !3
19 (I) 1 4.50 !4 — !3
21 (O) 1 5.89 !4 — !3
Mean 1 year 5.06
27 (G)b 0 8.28 7.3 6.2 4.6 —
27 (G) 0 7.63 5 5.3 3.7 —
19 (I)b 0 6.57 NA NA NA NA
Mean unsuppressed 7.49
NOTE. FDC, follicular dendritic cells; LN, lymph node; MNC, mononuclear cells; NA, not available.
a Capital letters indicate patient designations reported elsewhere [8, 11, 26, 27].
b Samples analyzed in earlier phase of study and reported elsewhere [8].
were deposited in GenBank (accession nos. AF185840–AF185849,
AF185863–AF185872, and AF337215–AF337318).
Results
Patient classification. For the analysis, patients were strati-
fied into 3 groups, according to the level of suppression of serum
viremia: group 1 included 18 patients with suppression of serum
viremia to below the level of detection (!50 copies/mL) for 2
years before the present study. At the approximate time that
LN biopsy specimens and CSF and GU secretions were ob-
tained, 4 group 1 patients had detectable viremia at low levels
(table 1); these subsequently became undetectable. Each of these
4 and 6 additional group 1 patients had the blood virologic
response pattern of good long-term suppression but with in-
termittent low-level viremia that has been described elsewhere
[16, 36]. Group 2 comprised 7 patients who had undetectable
serum HIV RNA levels for ∼1 year before the study. Group 3
consisted of 3 patients with detectable (range, 1500–2400 HIV
RNA copies/mL) serum viremia at year 2.
LN HIV-1 RNA. After 2 years of therapy, LN biopsy speci-
mens were obtained from 20 patients (table 1). Samples from
4 patients (group 1, 2; group 2, 2) had insufficient cellularity
for reliable quantitation, as measured by TCR Ca mRNA
(!12,500 copies or ∼500 T cell equivalents). In 3 group 1 pa-
tients, LN biopsy specimens had been obtained previously after
1 year of therapy [8].
HIV RNA was quantifiable from LNs with sufficient cellu-
larity from all 16 patients, including those with the most sus-
tained suppression of serum viremia (range, 2.2–6.8 log10 copies/
copies of TCR Ca mRNA). HIV RNA levels were64 10
similar among patients with suppression of viremia (!50 copies/
mL) for 1 year (mean HIV RNA level, 3.3 log10 copies/
copies of TCR Ca mRNA) and 2 years (mean HIV64 10
RNA level, 2.9 log10 copies/ copies of TCR Ca mRNA;64 10
table 1). Furthermore, LN HIV RNA levels did not change in
patients sampled at both years 1 and 2 (table 2). Among group
1 patients, LN HIV RNA concentrations did not differ signifi-
cantly between those with or without intermittent viremia after
initial reduction of viremia to !50 copies/mL (data not shown).
ISH and QIA demonstrated no FDC-associated virus at a
limit of detection of 4 log10 copies/g of tissue for patients with
suppression of viremia for 1 or 2 years. However, rare mono-
nuclear cells associated with low copy numbers of HIV RNA
were detectable in 2 of 5 patients with !50 copies/mL of serum
for 2 years and in 1 of 5 patients with undetectable viremia
after 1 year (table 2). These cells were shown previously to be
of lymphocytic lineage [3, 8].
LN HIV-1 DNA. Proviral HIV DNA was detectable in all
LN biopsy specimens with sufficient cellularity (range, 1–147
HIV DNA copies/100 ng of total genomic DNA). A cross-
sectional analysis between patients with serum viremia sup-
pressed for 1 or 2 years revealed no difference in proviral DNA
levels (table 1). Yet, in 2 of 3 group 1 patients (patients 2 and
3; table 1) from whom sequential LN biopsy specimens were
obtained at both years 1 and 2, second-year HIV DNA levels
were lower than first-year levels.
CSF HIV RNA. In CSF of 13 patients at year 2 after
initiation of potent therapy, none had detectable HIV RNA
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Figure 1. Serum human immunodeficiency virus type 1 (HIV-1) RNA from 4 patients with available clonal HIV env sequences plotted against
time of treatment with indinavir (Idv), zidovudine (Zdv), and lamivudine (3TC), according to Merck 035 study protocol. Serum HIV RNA
concentrations were measured by Roche ultrasensitive assay (limit of detection, 50 copies/mL). Antiretroviral treatment was initiated at week 0.
Arrows indicate time points when inguinal lymph node biopsy specimens were obtained. Patient designations 3, 2, 19, and 27 correspond to
patients B, C, I, and G, respectively, as reported elsewhere [8, 11, 26, 27]. Patients 19 and 27 received Zdv/3TC for the first 40 weeks and then
Zdv/3TC/Idv for the remaining study.
(!50 copies/mL). In 9 of these patients, HIV serum RNA was
suppressed below the limit of detection (50 copies/mL) at the
time point when CSF samples were obtained.
Genital secretion HIV RNA. Genital secretions were ex-
amined from 23 patients (21 men and 2 women). Between years
1 and 2, 22 of these patients had undetectable serum viremia
(!50 copies/mL). In 1 patient, HIV serum RNA was intermit-
tently detectable at low levels. Three of 23 patients had de-
tectable HIV RNA in cell-free genital secretions (1 of 21 men
and 2 of 2 women) in initial collections. The man had unde-
tectable viremia for 1 year, whereas both women had suppres-
sion of viremia for 2 years. Repeat assays on samples from
these 3 patients obtained 4–6 months later did not reveal de-
tectable HIV RNA.
Evolution of HIV env. To characterize further the residual
HIV RNA from LNs at years 1 and 2, the C2-V3 region of
HIV-1 env of RNA extracted from LNs from 3 patients with
undetectable HIV serum RNA at year 2 (patients 2 and 3 in
group 1; patient 19 in group 2) was amplified and sequenced.
In addition, patient 27, who had detectable RNA during most
of the observation period, served as a positive control for con-
tinuous viral replication. Figure 1 shows longitudinal HIV se-
rum RNA levels of these 4 patients.
We did phylogenetic analysis by using the neighbor-joining
method with all sequences generated, including a number of
laboratory strains to screen for contamination (NL4-3, YU2,
JRFL, SF 162, NY5, BAL, JRCSF, HXB2, and ADA; data
not shown). To determine the extent of evolutionary divergence
of env between sampled populations during HAART, we esti-
mated net nucleotide divergence between the subpopulations
(total divergence minus average within-sample diversity). Net
divergence more accurately reflects the amount of evolutionary
divergence between populations than total divergence. When
there is within-sample diversity, total divergence may be 10,
even if no evolution has occurred. Nucleotide divergence be-
tween baseline clonal sequences and LN sequences obtained at
years 1 and 2 revealed no discernible evolution for patient 3
(table 3). However, patient 2, who had a slower RNA decay
and 1 intermittently detectable HIV RNA level during the first
year of therapy showed evidence of evolution by total diver-
gence but none when net divergence was analyzed. Patient 19
showed evolution between baseline plasma sequences and year
1 and an increase of net divergence at year 2 in the absence of
any discernible serum viremia. A maximum likelihood tree re-
vealed, however, that LN year 2 sequences were phylogeneti-
cally older than plasma sequences, which suggests that these
JID 2001;183 (1 May) Residual HIV after Viremia Suppression 1323
Table 3. Total and net nucleotide divergence from human immu-
nodeficiency virus (HIV)–1 env sequences obtained from plasma and
lymph nodes (LNs) from 4 patients, by the Tamura-Nei model of
substitution.
Patient, populations compareda
Percentage total
divergence (SE)
Percentage net
divergence (SE)
3 (B)
Plasma year 0 vs. LN year 1 0.45 (0.16) 0.03 (0.10)
Plasma year 0 vs. LN year 2 0.49 (0.20) 0.03 (0.20)
LN year 1 vs. LN year 2 0.42 (0.18) 0.09 (0.17)
2 (C)
Plasma year 0 vs. LN year 2 (a) 3.40 (0.63) 0.00 (0.10)
Plasma year 0 vs. LN year 2 (b) 3.72 (0.61) 0.01 (0.08)
LN year 2 (a) vs. LN year 2 (b) 3.21 (0.58) 0.04 (0.08)
19 (I)
Plasma year 0 vs. LN year 1 3.23 (0.55) 0.39 (0.15)
Plasma year 0 vs. LN year 2 2.43 (0.60) 1.12 (0.63)
LN year 1 vs LN year 2 3.29 (0.67) 1.38 (0.68)
27 (G)
Plasma year 0 vs plasma year 2 2.98 (0.65) 1.18 (0.45)
Plasma year 0 vs LN year 1 3.47 (0.65) 0.42 (0.17)
Plasma year 0 vs LN year 2 4.01 (0.73) 1.39 (0.45)
LN year 1 vs. plasma year 2 3.76 (0.81) 1.89 (0.57)
LN year 2 vs plasma year 2 1.54 (0.38) 0.10 (0.15)
LN year 1 vs. LN year 2 4.83 (0.87) 2.14 (0.59)
NOTE. Nos. “1” and “2” indicate no. of years after initiation of potent
antiretroviral therapy when LN biopsy or plasma sample was obtained. “(a)”
and “(b)” indicate clonal sequences obtained from different extractions from 2
different fragments of patient C LN at year 2.
a Patient designations 3, 2, 19, and 27 correspond to B, C, I, and G, respectively,
as reported elsewhere [8, 11, 26, 27].
Figure 2. Maximum-likelihood phylogenetic tree for patient 19 shows
sequence relationships of human immunodeficiency virus (HIV) env
clones derived from serum collected at start of therapy and from se-
quences derived from lymph node HIV RNA at years 1 and 2. Individual
clones were compared with NL4-3 reference sequence. Genetic distances
(indicated by horizontal branch lengths) correspond to approximate per-
centage nucleotide differences. Clonal sequences from year 2 clustered
with shorter branch lengths to the inferred “most recent common an-
cestor” (nearest node basal to all patient clones), which suggests that the
year 2 clones are ancestral to baseline and year 1 clones.
RNA transcripts originated from a cell population containing
archival HIV variants, compared with baseline plasma se-
quences (figure 2). As expected, in patient 27, who had de-
tectable serum viremia for almost 2 years, there was significant
evolution between sequences at each time point (baseline, year
1, and year 2). Mean pairwise distances were positively cor-
related with net AUC HIV serum RNA (figure 3).
Discussion
Two major obstacles for the elimination of HIV in patients
receiving potent combination therapy have been defined: a pool
of latently infected resting CD4 T cells [26, 37, 38] and ongoing
low level viral replication in some patients with undetectable
or very low levels of serum viremia for prolonged periods [11,
12, 15–17, 39–41]. Evidence for these 2 mechanisms has been
based primarily on studies of peripheral blood mononuclear
cells (PBMC) [11, 13, 16, 17, 40, 42] and plasma [39, 41]. Recent
speculation has suggested that sanctuary sites, such as the CNS
and the genital tract, might account for such low level repli-
cation because of lower accessibility for drugs or because of
differences in cell turnover of infected cell types [42–44]. Yet,
published studies addressing compartmentalization issues of the
CNS and of genital secretions rarely investigated more than 2
different compartments simultaneously [23]. To investigate
whether the CNS, the genital tract, or lymphoid tissue might
be the sites of persistent viral replication in patients receiving
potent long-term antiretroviral therapy, we undertook the pres-
ent study to assess residual HIV in these compartments.
The persistence of HIV DNA in LN of persons with sup-
pression of viremia was expected, on the basis of the reported
longevity of latently infected cells and persistence of defective
genomes [16, 26, 37, 38, 45, 46]. However, detection of viral
RNA in LNs was uncertain. Given earlier estimates of the
clearance rate of lymphoid tissue associated viral RNA from
ISH-QIA studies for the first 6 months of therapy, our expec-
tation had been that, for patients with plasma HIV RNA levels
consistently !50 copies/mL, HIV RNA in lymphoid tissues
should have been reduced further during year 2 of treatment,
in some cases to undetectable levels.
Analysis of the RNA data by normalization of TCR Ca
mRNA permitted the exclusion of samples with inadequate cel-
lularity and corrected for differences in RNA extraction or PCR
amplification efficiency. Calculated in this manner, there was little
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Figure 3. Regression analysis of area under curve (AUC) net and net
divergence between clonal human immunodeficiency virus (HIV) env se-
rum sequences obtained from baseline serum RNA and lymph node or
plasma (PL) sequences at years 1 or 2 from 4 patients (Pts). AUCnet was
calculated as the difference between RNA productconcentration time
observed and RNA product predicted (based onconcentration time
ideal decay characteristics) and is used to provide a measure of residual
viral replication under potent therapy, as described in detail elsewhere
[12]. Patient designations 3, 2, 19, and 27 correspond to B, C, I, and G,
respectively, as reported elsewhere [8, 11, 26, 27]. No. after slash is time
after initiation of antiretroviral therapy (1, year 1; 2, year 2). PL indicates
divergence obtained between plasma sequences. If not otherwise stated,
divergence was generated between baseline plasma and lymph node se-
quences. , (pairwise correlation); Spearman2r p .8222 Pp .0019 rp
, ; Kendall , .0.9 Pp .0002 tp 0.79 Pp .0065
difference in viral RNA levels between years 1 and 2 either in
the 3 patients for whom biopsies were done at both time points
or in a cross-sectional comparison of all LN biopsy specimens
after 1 and 2 years of suppressive therapy. When RNA levels
were simply normalized to the mass of tissue extracted (but with
exclusion of samples with inadequate levels of TCR CamRNA),
a trend toward slightly lower RNA concentrations was noted at
year 2, compared with year 1; nevertheless, the apparent decay
of HIV RNA levels from year 1 to year 2 appears to be slower
than that previously observed for the first 6 months of therapy
as the second phase of decay [9]. A tendency toward lower HIV
DNA levels at year 2 also was observed in patients who under-
went sequential LN biopsies. However, few patients had serum
viremia !50 copies/mL with serial biopsies, and cross-sectional
comparisons may be suboptimal.
The persistence of viral RNA in LNs from patients with !50
copies/mL of HIV RNA for 2 years may reflect ongoing viral
replication in all patients, as other investigators have postulated
[12, 13, 15, 39–41], or a change in the rate of clearance of LN-
associated RNA following the initial reduction over the first
6–12 months of therapy. The data presented argue against the
possibility that the residual lymphoid HIV RNA originates
from sanctuary sites such as the CNS or the GU tract. No HIV
RNA was detected in the CSF in any of the 13 patients tested
(of whom 10 underwent LN biopsies; table 1). No HIV RNA
was detected in GU secretions from 20 of 23 patients tested for
genital secretions (15 underwent LN biopsies; table 1). In the
3 patients with genital secretions positive for HIV RNA, de-
tection was only transient. However, our assays might not have
been sensitive enough to detect very low levels of HIV RNA
in CSF and genital secretions. No baseline levels from these 2
compartments were available, and brain parenchyma and cel-
lular components of genital secretions could not be assessed.
In all patients with undetectable serum RNA levels that were
examined by ISH with QIA, no FDC-associated signal was
detectable with a sensitivity of detection of 104 copies/g of tissue.
Because this is approximately the concentration of viral RNA
that was detected by bulk RNA analysis, the ISH data do not
exclude the FDC network as the reservoir of residual viral RNA
in the form of trapped virus. Hlavacek et al. [47] recently sug-
gested that FDC-bound virus might decay very slowly, by tak-
ing into account a model that assumes binding of HIV by
ligand-receptor interactions. Such low levels of FDC-bound
virus may well be below the level of detection of ISH methods,
as described by several groups who used different detection
systems [9, 10, 48].
Cavert et al. [8, 9] observed that a small population of lym-
phocytes associated with low copy numbers persist after therapy
for 6 months to 1 year. A few of the patients studied by ISH in
the present study had identifiable cells with detectable virus when
we used a prolonged exposure capable of detecting 2 or 3 copies
of HIV RNA/cell. These cells might belong to a recently described
T cell population that produces viral RNA in a nonactivated
state and that persists in patients treated with potent antiretro-
viral therapy [3]. Such cells might contribute to the residual viral
RNA that was detected by bulk RNA quantitation and may
represent a reservoir of chronically infected cells or a form of
latently infected cells with low-level HIV transcription.
What is the origin of the residual RNA in LN? To address
this question, we did phylogenetic analyses from clonal enve-
lope sequences obtained directly from residual LN HIV RNA,
to determine whether HIV in lymphoid tissues of patients with
undetectable serum RNA levels showed sequence differences as
a marker of ongoing replication or as evidence of virus pro-
duction in distinctive tissue compartments.
For the patient with the highest level of suppression (patient
3; figure 1), no significant evolution of HIV env was detected
in residual LN RNA from biopsy specimens at years 1 and 2.
This finding does not support continuous viral replication, al-
though extremely low levels of replication insufficient to pro-
duce sequence change cannot be excluded. However, the se-
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quence analyses would be consistent with either virus
production from long-lived latently infected cells that were tran-
scriptionally active but did not give rise to new cycles of in-
fection or with the persistence of FDC-trapped virions pro-
duced before suppressive therapy.
In theory, HIV RNA could have been produced in a different
compartment, and virus could have been trapped in the FDC
network at quantities below the detection limit for ISH. Indeed,
cervical secretions at year 2 were positive for patient 3 (table
1) but subsequently became negative. However, sequences from
different time points and blood and lymphoid tissue sampled
were indistinguishable in a maximum likelihood tree that ren-
dered such a possibility improbable, given the effects that dif-
fering selective pressures in tissue compartments (e.g., the GU
and CNS) would be expected to have on the local virus quasi
species [18, 49]. The uniformity of the sequences obtained from
patient 3 are unlikely to reflect contamination artifacts. Since
env PCR amplification and sequencing from baseline plasma
were done 1 year before amplification and sequencing from
LNs. Sampling artifacts also seem unlikely because 2 different
LN biopsies were done 1 year apart and because PCRs were
done in quadruplicate to minimize sampling error.
Moreover, envelope sequences derived from in vitro–acti-
vated CD8-depleted PBMC at year 2 that presumably were
isolated from latently infected CD4 T cells [11, 26] did not differ
from sequences derived directly from HIV LN RNA or from
baseline plasma sequences in a maximum likelihood tree (data
not shown). Additional extensive clonal analysis obtained from
year 2 isolates from the latent reservoir from this patient did
not reveal any new mutation associated with drug resistance,
compared with baseline plasma [50]. Thus, despite rigorous
genetic analysis of HIV env and pol from different compart-
ments, viral replication could not be inferred by evolutionary
studies, even though HIV RNA was still detectable in the LN
and did not decay significantly over this time.
In contrast to patient 3, patients 2, 19, and 27 showed various
degrees of evolution of envelope sequences (table 3), which
correlated strongly with the extent of viral replication, as ex-
pressed by the AUCnet of longitudinal serum HIV RNA mea-
surements (figure 3). Of note, patient 19 had a significant net
sequence divergence from baseline to year 1, when serum vi-
remia was detectable and, contrary to expectations, even greater
divergence by year 2, despite serum virus load of !50 copies/
mL throughout year 2 (table 3). By maximum likelihood phy-
logeny the year 2 LN sequences appeared to be ancestral to
the initial plasma virus (figure 2), which suggests that residual
LN RNA resulted from long-lived chronically infected cells with
transcriptional activity possibly established before the baseline
time point from old FDC-bound virus with very slow decay or
from virus produced by activated archival latently infected cells
[51].
Chun et al. [42] recently reported that rebounding plasma
virus after cessation of potent long-term suppressive antiretro-
viral therapy in HIV-infected patients differed from virus iso-
lated from the latent pool before virus rebound. These differ-
ences were found by heteroduplex mobility assay (HMA) and
were thought to indicate that rebounding plasma virus origi-
nated from sanctuary sites such as the CNS or GU tract [42].
The present data suggest an alternative explanation for their
findings. The differences observed by Chun et al. between iso-
lates from the latent reservoir and rebounding virus off therapy
detected by HMA may reflect plasma virus produced by acti-
vation of latently infected cells harboring ancestral genotypes,
compared with those isolated by coculture while receiving ther-
apy [51].
In conclusion, our data show that the lymphoid compartment
remains an important reservoir for residual HIV in patients
successfully treated with combination antiretroviral therapy
who achieve undetectable HIV serum RNA levels for2 years.
In the patient without viral evolution of HIV RNA envelope
sequences directly obtained from LNs between years 1 and 2,
the absence of significant decay of HIV RNA from year 1 to
year 2 in these LNs raises the possibility of a slower third phase
of viral decay independent of residual viral replication or that
ongoing replication with negligible sequence evolution is oc-
curring. In the quest for more effective suppression of viral
replication, these findings indicate a more immediate need for
treatment strategies with greater antiviral potency in all com-
partments rather than for specialized regimens that target the
CNS or GU tract.
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